Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions

E. M FROHMAN; M FILIPPI; N MONSON; J DE KEYSER; H HARTUNG; L STEINMAN; J. R OKSENBERG; B. A. C CREE; S HAUSER; M. K RACKE; O STUVE; S. G WAXMAN; J CORBOY; J. T PHILLIPS; C LUCCHINETTI; J WILKEN; N KARANDIKAR; B HEMMER

doi:10.1001/archneur.62.9.1345

Back

Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions

Journal article

Open access

Peer reviewed

Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions

E. M FROHMAN, M FILIPPI, N MONSON, J DE KEYSER, H HARTUNG, L STEINMAN, J. R OKSENBERG, B. A. C CREE, S HAUSER, M. K RACKE, …

Archives of neurology (Chicago), Vol.62(9), pp.1345-1356

2005

DOI: 10.1001/archneur.62.9.1345

PMID: 16157741

Files and links (1)

url

https://doi.org/10.1001/archneur.62.9.1345View

Published (Version of record) Open Access

Abstract

Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.

Neurology

Biological and medical sciences

Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis

Medical sciences

Immunomodulators

Pharmacology. Drug treatments

Details

Title: Subtitle: Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions
Creators: E. M FROHMAN - Department of Neurology, University of Texas Southwestern Medical Center at Dallas, United States
M FILIPPI - Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
N MONSON - Department of Neurology, University of Texas Southwestern Medical Center at Dallas, United States
J DE KEYSER - Department of Neurology, University of Groningen, Groningen, Netherlands
H HARTUNG - Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
L STEINMAN - Department of Neurology, Stanford University, Stanford, Calif, United States
J. R OKSENBERG - Department of Neurology, University of California, San Francisco, United States
B. A. C CREE - Department of Neurology, University of California, San Francisco, United States
S HAUSER - Department of Neurology, University of California, San Francisco, United States
M. K RACKE - Department of Neurology, University of Texas Southwestern Medical Center at Dallas, United States
O STUVE - Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
S. G WAXMAN - Department of Neurology, Yale University, New Haven, Conn, United States
J CORBOY - Department of Neurology, University of Colorado, Boulder, United States
J. T PHILLIPS - Texas Neurology, Dallas, United States
C LUCCHINETTI - Department of Neurology, Mayo Clinic, Rochester, Minn, United States
J WILKEN - Division of Neuropsychology, Department of Veterans Affairs, Washington, DC, United States
N KARANDIKAR - Department of Neurology, University of Texas Southwestern Medical Center at Dallas, United States
B HEMMER - Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Resource Type: Journal article
Publication Details: Archives of neurology (Chicago), Vol.62(9), pp.1345-1356
DOI: 10.1001/archneur.62.9.1345
PMID: 16157741
NLM abbreviation: Arch Neurol
ISSN: 0003-9942
eISSN: 1538-3687
Publisher: American Medical Association; Chicago, IL
Language: English
Date published: 2005
Academic Unit: Pathology
Record Identifier: 9984047864202771

Metrics

24 Record Views

91 Times Cited - Web of Science